TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients

Vancouver, British Columbia--(Newsfile Corp. - December 8, 2025) - TempraMed Technologies Ltd. (CSE: VIVI) ("TempraMed" or the "Company"), a medical technology innovator transforming how temperature-sensitive medications are stored and managed, is pleased to announce a major commercial milestone as part of its broader global expansion strategy: its flagship products, the VIVI Cap and VIVI EPI, are now available through Maccabi Healthcare Services, Israel's second-largest health maintenance organization (HMO) serving over 2.8 million members.

This commercial rollout marks a significant inflection point for TempraMed as it enters the next phase of its growth, scaling its innovative temperature-control platform through strategic healthcare partnerships and distribution channels globally. The Company has already sold over 120,000 devices globally and is sold through Amazon, Target, Walgreens, Walmart, CVS, McKesson, Cardinal Health and Humana (Top 5 largest Medical Payor in the United States).

Designed to protect insulin and EpiPen™ pens from temperature extremes, the VIVI Cap and VIVI Epi use a unique and patented combination of deep vacuum insulator and phase-change materials to maintain a safe temperature range for "in use" injectables, without the need for batteries, refrigeration, or external power. This lightweight, reusable device empowers people with diabetes or others using injectables to live active, independent lives-whether at the beach, traveling, or during daily routines.

The agreement with Maccabi exemplifies TempraMed's strategy to build a global, category-defining brand in personal medication protection, with a particular focus on chronic conditions such as diabetes, weight management, anaphylaxis where consistent medication efficacy is essential for quality of life and long-term outcomes.

"This milestone is more than just a commercial agreement-it's a validation of our long-term vision and growth strategy," said Ron Nagar, CEO of TempraMed. "By partnering with an innovative leader like Maccabi, we're accelerating access to life-enhancing technology for millions who need it. Our vision is to lead the global standard for smart medication protection, and this partnership is an exciting step forward as we scale across markets and product categories."